Status of vaccine research and development of vaccines for dengue

Vaccine

Volumn 34, Issue 26, 2016, Pages 2934-2938

  Vannice, Kirsten S ^a   Durbin, Anna ^b   Hombach, Joachim ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical pipeline; Dengue vaccine; Vaccine development

Indexed keywords

DENGUE VACCINE; RECOMBINANT VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; CD8+ T LYMPHOCYTE; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG RESEARCH; FOLLOW UP; HUMAN; IMMUNE RESPONSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; SEROTYPE; ANIMAL; CLINICAL TRIAL (TOPIC); MEDICAL RESEARCH; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DENGUE; DENGUE VACCINES; HUMANS; VACCINES, SYNTHETIC;

EID: 84961267244     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.12.073     Document Type: Article

References (61)

1. Guzman M.G., Harris E. Dengue. Lancet 2015, 385:453-465.
2. Achee N.L., Gould F., Perkins T.A., Reiner R.C., Morrison A.C., Ritchie S.A., et al. A critical assessment of vector control for dengue prevention. PLoS Negl Trop Dis 2015, 9:e0003655.
3. Kraemer M.U., Sinka M.E., Duda K.A., Mylne A.Q., Shearer F.M., Barker C.M., et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. Elife 2015, 4:e08347.
4. World Health Organization. Global Strategy for dengue prevention and control, 2012-2020. Geneva, Switzerland 2012.
5. Simmons C.P., Farrar J.J., Nguyen V.V., Wills B. Dengue. N Engl J Med 2012, 366:1423-1432.
6. Beatty M.E., Beutels P., Meltzer M.I., Shepard D.S., Hombach J., Hutubessy R., et al. Health economics of dengue: a systematic literature review and expert panel's assessment. Am J Trop Med Hyg 2011, 84:473-488.
7. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496:504-507.
8. Cummings D.A., Iamsirithaworn S., Lessler J.T., McDermott A., Prasanthong R., Nisalak A., et al. The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling. PLoS Med 2009, 6:e1000139.
9. World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control. Geneva, Switzerland 2009.
10. Prevention. UCfDCa. Laboratory guidance and diagnostic testing; 2012.
11. Monath T.P. Dengue: the risk to developed and developing countries. Proc Natl Acad Sci USA 1994, 91:2395-2400.
12. Simmons C.P., McPherson K., Van Vinh Chau N., Hoai Tam D.T., Young P., Mackenzie J., et al. Recent advances in dengue pathogenesis and clinical management. Vaccine 2015, 33(50):7061-7068.
13. Shepard D.S., Coudeville L., Halasa Y.A., Zambrano B., Dayan G.H. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg 2011, 84:200-207.
14. Halstead S.B. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 2013, 31:4501-4507.
15. Reich N.G., Shrestha S., King A.A., Rohani P., Lessler J., Kalayanarooj S., et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface 2013, 10:20130414.
16. Burke D.S., Nisalak A., Johnson D.E., Scott R.M. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988, 38:172-180.
17. Hombach J. Guidelines for clinical trials of dengue vaccine in endemic areas. J Clin Virol 2009, 46(Suppl 2):S7-S9.
18. Comisión Federal para la Protección contra Riesgos Sanitarios. MÉXICO APRUEBA LA PRIMERA VACUNA CONTRA EL VIRUS DEL DENGUE A NIVEL MUNDIAL; 2015.
19. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
20. Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384:1358-1365.
21. Villar L., Dayan G.H., Arredondo-Garcia J.L., Rivera D.M., Cunha R., Deseda C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015, 372:113-123.
22. Hadinegoro S.R., Arredondo-Garcia J.L., Capeding M.R., Deseda C., Chotpitayasunondh T., Dietze R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015, 373:1195-1206.
23. Simmons C.P. A candidate dengue vaccine walks a tightrope. N Engl J Med 2015, 373:1263-1264.
24. Guy B., Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 2015, 14(1):45-54.
25. Addendum to report of the Global Advisory Committee on Vaccine Safety (GACVS), 10-11 June 2015(1). Safety of CYD-TDV dengue vaccine. Wkly Epidemiol Rec 2015, 90:421-423. World Health Organization.
26. Flipse J., Smit J.M. The complexity of a dengue vaccine: a review of the human antibody response. PLoS Negl Trop Dis 2015, 9:e0003749.
27. Bentsi-Enchill A.D., Schmitz J., Edelman R., Durbin A., Roehrig J.T., et al. Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation. Vaccine 2013, 31:2603-2609. Live Dengue Vaccines Technical Consultation Reporting Group.
28. Mahoney R.T., Francis D.P., Frazatti-Gallina N.M., Precioso A.R., Raw I., Watler P., et al. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine 2012, 30:4892-4896.
29. ClinicalTrials.gov. Safety and immunogenicity of different schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in healthy participants; 2015.
30. Clinicaltrials.gov. Safety and immunogenicity with two different serotype 2 potencies of Tetravalent Dengue Vaccine (TDV) in adults in Singapore; 2015.
31. Clinicaltrials.gov. Evaluating the safety of and immune response to a dengue vaccine (TV003) in healthy adults, adolescents, and children in Thailand 2015.
32. Clinicaltrials.gov. Phase III trial to evaluate efficacy and safety of a tetravalent dengue vaccine 2015.
33. World Health Organization. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated) technical report series. Geneva, Switzerland 2013.
34. Hombach J., Cardosa M.J., Sabchareon A., Vaughn D.W., Barrett A.D. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 2007, 25:4130-4139.
35. Jackson N., Boaz M., Hu B., Langevin E., Byers A., Baric R., et al. Abstract 576: investigations of the observed efficacy of the CYD tetravalent dengue vaccine in the Phase 2b trial in Ratchaburi, Thailand. Am J Trop Med Hyg 2014, 91:172.
36. Buddhari D., Aldstadt J., Endy T.P., Srikiatkhachorn A., Thaisomboonsuk B., Klungthong C., et al. Dengue virus neutralizing antibody levels associated with protection from infection in Thai cluster studies. PLoS Negl Trop Dis 2014, 8:e3230.
37. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
38. Weiskopf D., Angelo M.A., de Azeredo E.L., Sidney J., Greenbaum J.A., Fernando A.N., et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA 2013, 110:E2046-E2053.
39. Sariol C.A., White L.J. Utility, limitations, and future of non-human primates for dengue research and vaccine development. Front Immunol 2014, 5:452.
40. Larsen C.P., Whitehead S.S., Durbin A.P. Dengue human infection models to advance dengue vaccine development. Vaccine 2015, 33(50):7075-7082.
41. Mammen M.P., Lyons A., Innis B.L., Sun W., McKinney D., Chung R.C., et al. Evaluation of dengue virus strains for human challenge studies. Vaccine 2014, 32:1488-1494.
42. Sun W., Eckels K.H., Putnak J.R., Lyons A.G., Thomas S.J., Vaughn D.W., et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis 2013, 207:700-708.
43. Durbin A.P., Kirkpatrick B.D., Tibery C., Grier P., Pierce K.K., Larsson C.J., et al. Abstract 1220: a single dose of TV003 elicits protective efficacy against challenge with a heterotypic dengue virus type 2. American Society of Tropical Medicine and Hygiene 2015.
44. Schwartz L.M., Halloran M.E., Durbin A.P., Longini I.M. The dengue vaccine pipeline: implications for the future of dengue control. Vaccine 2015, 33:3293-3298.
45. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Schmidt A.C., Whitehead S.S. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011, 29:7242-7250.
46. Kirkpatrick B.D., Durbin A.P., Pierce K.K., Carmolli M.P., Tibery C.M., Grier P.L., et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis 2015, 212(5):702-710.
47. Whitehead S.S. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine: what makes this vaccine different from the Sanofi-Pasteur CYD vaccine?. Expert Rev Vaccines 2015, [Epub ahead of print].
48. Osorio J.E., Huang C.Y., Kinney R.M., Stinchcomb D.T. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011, 29:7251-7260.
49. George S.L., Wong M.A., Dube T.J., Boroughs K.L., Stovall J.L., Luy B.E., et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial. J Infect Dis. 2015, 212(7):1032-1041.
50. Osorio J.E., Velez I.D., Thomson C., Lopez L., Jimenez A., Haller A.A., et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis 2014, 14:830-838.
51. Rupp R., Luckasen G.J., Kirstein J.L., Osorio J.E., Santangelo J.D., Raanan M., et al. Safety and immunogenicity of different doses and schedules of a live attenuated Tetravalent Dengue Vaccine (TDV) in healthy adults: a phase 1b randomized study. Vaccine 2015, 33:6351-6359.
52. Martinez L.J., Lin L., Blaylock J.M., Lyons A.G., Bauer K.M., De La Barrera R., et al. Safety and immunogenicity of a dengue virus serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial. Am J Trop Med Hyg 2015, 93(3):454-460.
53. Coller B.A., Clements D.E., Bett A.J., Sagar S.L., Ter Meulen J.H. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011, 29:7267-7275.
54. Govindarajan D., Meschino S., Guan L., Clements D.E., Ter Meulen J.H., Casimiro D.R., et al. Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates. Vaccine 2015, 33(33):4105-4116.
55. Beckett C.G., Tjaden J., Burgess T., Danko J.R., Tamminga C., Simmons M., et al. Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial. Vaccine 2011, 29:960-968.
56. Clinicaltrials.gov. TDENV PIV and LAV dengue prime-boost strategy; 2015.
57. Vannice K.S., Roehrig J.T., Hombach J. Next generation dengue vaccines: a review of the preclinical development pipeline. Vaccine 2015, 33(50):7091-7099.
58. Brandler S., Ruffie C., Najburg V., Frenkiel M.P., Bedouelle H., Despres P., et al. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 2010, 28:6730-6739.
59. Li Z., Yang H., Yang J., Lin H., Wang W., Liu L., et al. Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone. Virus Res 2014, 191:10-20.
60. Azevedo A.S., Goncalves A.J., Archer M., Freire M.S., Galler R., Alves A.M. The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue. PLoS One 2013, 8:e58357.
61. Kallenberg JAN. Report to the GAVI Alliance Board 21-22 November 2013. In: Alliance G, editor 2013.